ACKR3, R&D Systems, mab42273

In “Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments”, Tripathi et al study the specificity of 3 different antibodies against
atypical chemokine receptor 3 (ACKR3). The specificity of the antibodies was tested by flow cytometry using human vascular smooth muscle cell. Here, a fluorescent signal was measured when treated with siRNA specific for AKCR3 (Human CXCR7 (57007) (E-013212-00-0050)) and compared with the fluorescent signal from cells treated with non-targeting RNA.

When using this antibody, a 72% reduction in fluorescence was observed.

See full description in the article:
https://www.ncbi.nlm.nih.gov/pubmed/26660071